Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.

Wong KK, Fracasso PM, Bukowski RM, Lynch TJ, Munster PN, Shapiro GI, Jänne PA, Eder JP, Naughton MJ, Ellis MJ, Jones SF, Mekhail T, Zacharchuk C, Vermette J, Abbas R, Quinn S, Powell C, Burris HA.

Clin Cancer Res. 2009 Apr 1;15(7):2552-8. doi: 10.1158/1078-0432.CCR-08-1978. Epub 2009 Mar 24.

2.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B.

Oncologist. 2007 Apr;12(4):426-37. Review.

3.

Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.

Bose P, Ozer H.

Expert Opin Investig Drugs. 2009 Nov;18(11):1735-51. doi: 10.1517/13543780903305428. Review.

PMID:
19780706
4.

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

Medina PJ, Goodin S.

Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Review.

PMID:
18803986
5.

A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.

Patnaik A, Rowinsky EK, Villalona MA, Hammond LA, Britten CD, Siu LL, Goetz A, Felton SA, Burton S, Valone FH, Eckhardt SG.

Clin Cancer Res. 2002 Jul;8(7):2142-8. Review.

6.

The development of HKI-272 and related compounds for the treatment of cancer.

Wissner A, Mansour TS.

Arch Pharm (Weinheim). 2008 Aug;341(8):465-77. doi: 10.1002/ardp.200800009. Review.

PMID:
18493974
7.

Neratinib (HKI-272) in the treatment of breast cancer.

López-Tarruella S, Jerez Y, Márquez-Rodas I, Martín M.

Future Oncol. 2012 Jun;8(6):671-81. doi: 10.2217/fon.12.66. Review.

PMID:
22764764
8.

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.

Nelson MH, Dolder CR.

Ann Pharmacother. 2006 Feb;40(2):261-9. Epub 2006 Jan 17. Review.

PMID:
16418322
9.

Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.

Kourie HR, Chaix M, Gombos A, Aftimos P, Awada A.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):947-57. doi: 10.1080/17425255.2016.1198317. Epub 2016 Jun 27. Review.

PMID:
27284682
10.

Lapatinib.

Dhillon S, Wagstaff AJ.

Drugs. 2007;67(14):2101-8; discussion 2109-10. Review. No abstract available.

PMID:
17883289
11.

Lapatinib-associated toxicity and practical management recommendations.

Moy B, Goss PE.

Oncologist. 2007 Jul;12(7):756-65. Review.

12.

HER family inhibitors in pancreatic cancer: current status and future directions.

Berz D, Miner T, McCormack E, Safran H.

Expert Opin Ther Targets. 2007 Mar;11(3):337-47. Review.

PMID:
17298292
13.

Review: side effects of approved molecular targeted therapies in solid cancers.

Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A.

Oncologist. 2007 Dec;12(12):1443-55. doi: 10.1634/theoncologist.12-12-1443. Review.

14.

Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.

De Luca A, Normanno N.

IDrugs. 2010 Sep;13(9):636-45. Review. Erratum in: IDrugs. 2010 Oct;13(10):742. Dosage error in article text.

PMID:
20799147
15.

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

Hotte SJ, Hirte HW.

Curr Pharm Des. 2002;8(25):2249-53. Review.

PMID:
12369852
16.

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW.

Semin Oncol. 2002 Jun;29(3 Suppl 11):11-21. Review.

PMID:
12138393
17.

Su-6668. SUGEN.

Fabbro D, Manley PW.

Curr Opin Investig Drugs. 2001 Aug;2(8):1142-8. Review.

PMID:
11892927
18.

Profile of neratinib and its potential in the treatment of breast cancer.

Feldinger K, Kong A.

Breast Cancer (Dove Med Press). 2015 Jun 9;7:147-62. doi: 10.2147/BCTT.S54414. eCollection 2015. Review.

19.

Molecular targeted therapies for solid tumors: management of side effects.

Grünwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J.

Onkologie. 2009 Mar;32(3):129-38. doi: 10.1159/000194949. Epub 2009 Feb 16. Review.

PMID:
19295254
20.

Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn?

Dewji MR.

J Chemother. 2004 Nov;16 Suppl 4:44-8. Review.

PMID:
15688609

Supplemental Content

Support Center